Lamogin 50 mg (Tablet)
Unit Price: ৳ 18.00 (3 x 10: ৳ 540.00)
Strip Price: ৳ 180.00
Medicine Details
Category | Details |
---|---|
Generic | Lamotrigine |
Company | Incepta pharmaceuticals ltd |
Also available as |
Indications
- Adjunctive therapy for partial-onset seizures
- Adjunctive therapy for primary generalized tonic-clonic seizures
- Adjunctive therapy for generalized seizures of Lennox-Gastaut syndrome
- Monotherapy for epilepsy in patients aged 16 years and older
- Treatment of bipolar disorder in patients aged 18 years and older
Description
- Phenyltriazine antiepileptic
- Used to treat some types of epilepsy and bipolar disorder
- Controls epileptic seizures by inhibiting voltage-sensitive sodium channels
- Stabilizes neuronal membranes
- Inhibits presynaptic excitatory neurotransmitter release
Pharmacology
- Inhibits voltage-sensitive sodium channels
- Modulates the release of presynaptic excitatory neurotransmitters
- Binds to inactive sodium channels
- Suppresses the release of glutamate, an excitatory amino acid
- Binds to serotonin 5-HT3 receptor weakly
- Displays weak binding properties to Adenosine A1/A2 receptors, α1/α2/β adrenergic receptors, dopamine D1/D2 receptors, GABA A/B receptors, histamine H1 receptors, κ-opioid receptor, mACh receptors
- Weakly binds to sigma opioid receptors
- Inhibits Cav2.3 (R-type) calcium currents
Dosage & Administration
- Escalation regimen for Lamotrigine in epilepsy patients older than 12 years
- Escalation regimen for Lamotrigine in epilepsy patients aged 2 to 12 years
- Escalation regimen for Lamotrigine in adults with bipolar disorder
- Initial weight-based dosing guide for patients aged 2 to 12 years taking Valproate with epilepsy
Interaction
- Valproate increases Lamogin concentrations more than 2-fold
- Carbamazepine, phenytoin, phenobarbital, primidone, and rifampin decrease Lamogin concentrations by approximately 40%
- Estrogen-containing oral contraceptives decrease Lamogin concentrations by approximately 50%
- Protease inhibitors lopinavir/ritonavir and atazanavir/ritonavir decrease Lamogin exposure by approximately 50% and 32% respectively
Side Effects
- Dizziness
- Headache
- Diplopia
- Ataxia
- Nausea
- Blurred vision
- Somnolence
- Pharyngitis
- Rash
- Vomiting (in children)
- Diarrhea (in children)
- Infection (in children)
- Fever (in children)
- Abdominal pain (in children)
- Tremor (in children)
Pregnancy & Lactation
- Pregnancy Category C
- Excreted in human milk
- Potential for serious adverse reactions in nursing infants
- Decision should be made whether to discontinue nursing or discontinue the drug
Precautions & Warnings
- Discontinue at the first sign of rash
- Monitor for blood dyscrasias
- Monitor for signs of anemia, unexpected infection, or bleeding
- Monitor for suicidal thoughts or behaviors
- Monitor for signs of aseptic meningitis
Use in Special Populations
- Safety and effectiveness of Lamogin as adjunctive treatment for partial onset seizures not demonstrated in very young pediatric patients aged 1 to 24 months
- Safety and effectiveness of Lamogin for the maintenance treatment of bipolar disorder not established in pediatric patients aged 10 to 17 years
Overdose Effects
- Ataxia
- Nystagmus
- Seizures (including tonic-clonic seizures)
- Decreased level of consciousness
- Coma
- Intraventricular conduction delay
Therapeutic Class
- Primary anti-epileptic drugs
Storage Conditions
- Keep out of reach of children
- Store in a dry place
- Below 25°C temperature
- Protected from light